Primary Myeloid Sarcoma of the Prostate: A Case Report and Literature Review

Table 2

Secondary myeloid sarcoma of the prostate.

Case	Age	Symptoms	Hematological diagnosis	Time from systemic disease to MS	Treatment	Outcomes
7 [13]	61	Hematuria and frequency	AML	Diagnosed simultaneously	Doxorubicin, vincristine, cytarabine, and prednisone	Died 5.5 months after MS diagnosis
8 [14]	65	Urinary retention and weight loss	AML-M4 (FAB classification)	Diagnosed simultaneously	Chemotherapy (unspecified)	Died 3 weeks after MS diagnosis
9 [15]	72	Urinary retention	CMML	Diagnosed simultaneously	Etoposide	CMML progressed to AML at 3 months and then died at 4 months after MS diagnosis
10 [16]	N/A	Urinary retention	AML	Diagnosed simultaneously	Chemotherapy (unspecified)	Died; no details
11 [17]	8	Urinary retention	AML-M2 (FAB classification)	Diagnosed simultaneously	High-dose cytarabine	N/A
12 [18]	44	Lower urinary tract symptoms	AML	Diagnosed simultaneously	Chemotherapy and SCT	CR and further follow-up N/A
13 [13]	72	Urinary retention and testicular pain	MDS	11 months	RT to the prostate bed for hematuria	N/A
14 [19]	65	Asymptomatic, indurated PSA	AML-M5 (FAB classification)	13 months	RT and then salvage chemotherapy	Initially treated with RT, developed AML relapse at 2 months, and underwent salvage chemotherapy. Alive at 5 months after MS diagnosis
15 [20]	68	Urinary retention	AML-M2 (FAB classification)	9 years	RT and chemotherapy (unspecified)	Progressed to AML at 6 months after MS diagnosis and died during salvage chemotherapy shortly after
16 [6]	66	Asymptomatic, rising PSA	MDS status after SCT	6 months	Induction chemotherapy and donor lymphocyte infusion	CR and alive at 1 year after MS diagnosis

AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; FAB classification: French-American-British classification; MDS: myelodysplastic syndrome; MS: myeloid sarcoma; N/A: not available; PSA: prostate-specific antigen; SCT: stem cell transplant.